The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Biomarkers to Support Therapeutic Trials Program, 2023Developing a Novel Platform for Patient Selection and Disease Tracking Using Super-resolution Microscopy and AI
Study Rationale: The ability to track alpha-synuclein pathology in tissues outside the brain would facilitate accurate diagnosis of Parkinson's disease (PD), enable inclusion of individuals with alpha...
-
Translational Pipeline Program, 2023Exploring the Use of Molecules that Stabilize the Interaction between LRRK2 Kinase and the 14-3-3 Adapter Protein as a Neuroprotective Therapy for Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is associated with activating mutations in a protein kinase called LRRK2. In previous studies, we found that regulating LRRK2’s chemical modification by...
-
Research Grant, 2023A Novel Preclinical Candidate for Reducing Alpha-synuclein Aggregation in Parkinson’s Disease
Study Rationale: The goal of this program is to develop a novel drug for Parkinson’s disease (PD) with a unique mechanism of action. We have a drug candidate that shows potential as an inhibitor of...
-
Research Resources Imaging Program, 2023Development of Biomarkers Based on Brainstem Nuclei for Prodromal Parkinson's Disease
Study Rationale: Early diagnosis of Parkinson’s disease (PD) requires development of biomarkers that can be used to detect the first signs of neurodegeneration. Animal models suggest that tiny regions...
-
Cellular Phenotyping in Human iPSCS from the PPMI Cohort, 2023Studying Microglia Produced from Cell Lines Obtained from the Parkinson’s Progression Markers Initiative
Study Rationale: We have previously studied how different genetic variants associated with Parkinson’s disease (PD) affect dopamine neurons, which are the brain cells that degenerate in this disease...
-
Therapeutic Pipeline Program, 2023Evaluation of the Inflammation-blocking Drug Tolebrutinib as a Novel Disease-modifying Therapeutic for Parkinson's Disease
Study Rationale: Our project will test the effectiveness of a new treatment for Parkinson’s disease (PD). Developed by Sanofi, the drug — called Tolebrutinib — blocks inflammation in the brain. Based...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.